Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) plus F/TAF in treatment-naive HIV-1 positive adults: Week 96
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要